- Home
- ARCT vs KROS Comparison
ARCT vs KROS Comparison
Compare ARCT & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- KROS
- Stock Information
- Founded
- ARCT 2013
- KROS 2015
- Country
- ARCT United States
- KROS United States
- Employees
- ARCT N/A
- KROS N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- KROS Health Care
- Exchange
- ARCT Nasdaq
- KROS Nasdaq
- Market Cap
- ARCT 320.8M
- KROS 565.0M
- IPO Year
- ARCT N/A
- KROS 2020
- Fundamental
- Price
- ARCT $19.62
- KROS $16.04
- Analyst Decision
- ARCT Strong Buy
- KROS Buy
- Analyst Count
- ARCT 10
- KROS 14
- Target Price
- ARCT $50.88
- KROS $20.56
- AVG Volume (30 Days)
- ARCT 503.6K
- KROS 383.7K
- Earning Date
- ARCT 11-06-2025
- KROS 11-05-2025
- Dividend Yield
- ARCT N/A
- KROS N/A
- EPS Growth
- ARCT N/A
- KROS N/A
- EPS
- ARCT N/A
- KROS 0.47
- Revenue
- ARCT $122,122,000.00
- KROS $232,844,000.00
- Revenue This Year
- ARCT N/A
- KROS $5,998.31
- Revenue Next Year
- ARCT $28.92
- KROS N/A
- P/E Ratio
- ARCT N/A
- KROS $34.39
- Revenue Growth
- ARCT N/A
- KROS 85820.30
- 52 Week Low
- ARCT $8.04
- KROS $9.12
- 52 Week High
- ARCT $25.88
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- ARCT 67.57
- KROS 62.64
- Support Level
- ARCT $17.70
- KROS $15.34
- Resistance Level
- ARCT $19.50
- KROS $16.11
- Average True Range (ATR)
- ARCT 1.09
- KROS 0.44
- MACD
- ARCT 0.01
- KROS -0.01
- Stochastic Oscillator
- ARCT 98.01
- KROS 94.25
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.